Search

for
Search:

Research

5 / 1000+ results

research Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome

294 citations , March 2016 in “European journal of cancer”

This study found that neoadjuvant chemotherapy followed by interval debulking surgery led to better quality of life and lower perioperative morbidity compared to primary debulking surgery in advanced epithelial ovarian cancer patients with high tumor load.

research Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment

3 citations , April 2025 in “American Journal of Clinical Dermatology”

Baricitinib is generally safe for long-term use in treating severe alopecia areata.

Efficacy of Baricitinib in Adults with Alopecia Areata: Patients’ Perspectives on Hair Regrowth from Two Phase III Randomized Controlled Trials (BRAVE-AA1 and BRAVE-AA2)

research P79: Efficacy of baricitinib in adults with alopecia areata: patients’ perspectives on hair regrowth from two phase III randomized controlled trials (BRAVE‐AA1 and BRAVE‐AA2)

1 citations , July 2022 in “British Journal of Dermatology”

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

research Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata

44 citations , October 2009 in “Journal of the American Academy of Dermatology”

This study reported that 1% bexarotene gel was well tolerated and possibly effective for inducing partial hair regrowth in alopecia areata, but more rigorous trials are needed to confirm its efficacy.

research Phase I-II trial of weekly bicalutamide in men with high PSA and negative biopsy

1 citations , June 2007 in “Journal of Clinical Oncology”

This study found that weekly low-dose bicalutamide was safe and appeared to be associated with high-grade PIN remission and favorable PSA modulation in subjects with persistently elevated PSA but negative biopsy.

View more "phase iii" in research →

Community Join

5 / 1000+ results

community Breezula Phase III 12-Month Data Released by Cosmo Pharma

42 upvotes 5 months ago

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

community Pyrilutamide phase III clinical trial results released

in Research/Science 31 upvotes 2 years ago

Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.

community So why did the first pyrilutamide phase III fail?

4 upvotes 1 month ago

Pyrilutamide's inconsistent trial results, with phase II showing positive hair growth and phase III failing to show significant gains, possibly due to COVID-related disruptions. Users discuss modest results from kx-826 treatment.

community What the Breezula Phase III results mean & realistic timeline

59 upvotes 9 months ago

Breezula offers modest hair growth similar to finasteride and is expected to be available by late 2026. It is a safe alternative without hormonal side effects and works well with minoxidil.

community Breezula 6 Month Topline Phase III Results Released

172 upvotes 9 months ago

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

View more "phase iii" in community →

Learn

7 / 801 results

learn GT20029

When will GT20029 be commercially available, and are there any clinical trials on its use? GT20029 is not approved or commercially available anywhere and remains investigational. A published 12-week Phase II study in 180 Chinese men reports hair-count gains over placebo, but no long-term or Phase III data exists, so any launch is years away at best.

learn Clascoterone

Is clascoterone suitable for both men and women? Clascoterone is not approved for hair loss in either sex — the approved product is a 1% acne cream. The scalp version has completed phase III trials in men with sponsor-reported positive results; in women the only data is a company-reported phase II significant in one subgroup, so use is off-label and investigational for both.

learn KX-826

Kintor Pharmaceutical: KX-826, a New Name in Hair Loss Research KX-826 (pyrilutamide) is an experimental topical androgen receptor blocker from Kintor Pharmaceutical. It is not approved as a medicine anywhere; the company reports that its China Phase III trial met its primary endpoint at 24 weeks, but the trial data has been released through corporate announcements rather than peer-reviewed journals and long-term safety is unknown.

learn Pyrilutamide

What is pyrilutamide, and how does it help with androgenic alopecia or hair loss caused by DHT? Pyrilutamide (KX-826) is an investigational topical antiandrogen designed to block DHT at the androgen receptor in the scalp rather than lower DHT in the blood. Its sponsor has announced positive Phase III top-line results in China, but none of the data are peer-reviewed and it is not approved as a medicine anywhere.
Can pyrilutamide be used by both men and women, or only in specific cases? Pyrilutamide (KX-826) is an investigational topical anti-androgen that has been trialled in both men and women, but it is not approved for hair loss anywhere; the company reports that its China Phase III trial in men met its primary endpoint, but the data come from sponsor announcements rather than peer-reviewed journals, and long-term safety is unknown.